Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppal, R.R.District -500039, TS
Ph: +91-40-66200100 / 65523363
Url: www.combatdrugs.in Email: info@combatdrugs.in
CIN No.: L24230TG1986PLC006781
TIN: 36690236431
D.L.No.: TG/15/04/2016-14766

14/11/2016
To,
The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street,
Mumbai 400001

Sir,
Sub:

Outcome of Board Meeting Approval of Quarterly Results

(Quarter ended 30th September, 2016)

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of
the Board of Directors of the company held today ie; 14th November, 2016, the Statement of
Un-Audited Financial Results for the quarter ended 30th September, 2016 was approved and
taken on record along with the Limited Review Report for the period issued by the Statutory
Auditors of the company.
Please find enclosed the following in respect of the above said:
1. Statement of Un-Audited Financial Results for the Quarter ended 30th Sep, 2016.
2. Statement of Assests and Liabilities for the half year ended 30th Sep, 2016.
3. Limited Review Report of the Auditors on Quarterly Financial Results pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015.
This is for your information and records.
Thanking You
Yours Sincerely,
For COMBAT DRUGS LIMITED

Kiran Kumar K
COMPLIANCE OFFICER

COMBAT DRUGS LIMITED

Regd.off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppal, R.R.Dist - 39, TS

(CIN NO. CL23230TG1986PLC006781)

Ph:040-66200100 / 65523363 URL: www.combatdrugs.in
Mail: info@combatdrugs.in
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2016
Amount - Rs. In lakhs
Particulars
Quarter ended
Half Year ended
Yead ended
30.09.2016
30.06.2016
30.09.2015
30.09.2015
31.03.2016
30.09.2016
Unaudited

Unaudited

Unaudited

Unaudited

Unaudited

Audited

PART - I
1. Income from Operations
1 (a) Net Sales/Income from Operations (net of
excise duty)
(b) Other Operating Income

9.85

3.07

4.47

12.92

6.93

22.30

0.00

0.00

0.00

9.85

3.07

4.47

0.00
12.92

0.00
6.93

0.00
22.30

a. Cost of materials consumed

5.13

2.57

3.53

7.70

5.28

11.30

b. Purchase of stock-in-trade

0.00

0.00

0.00

0.00

0.00

0.00

c. Changes in inventories of Finished goods, workin-progress and stock-in-trade

d. Employees benefits expense

0.00

0.00

0.00
0.00

0.00

0.00

5.09

4.08

1.53

9.17

3.06

12.38

e. Depreciation

0.00

0.00

2.85

0.00

5.70

8.56

f. Expired stocks

0.00

0.00

0.00

0.00

0.00

39.92

g. Other expenses

5.45

4.56

7.52

15.67

11.21

15.43

10.01
26.88

13.25
27.29

78.46
150.62

(5.82)

(8.14)

(10.96)

(13.96)

(20.36)

(128.32)

0.00

0.00

0.15

5 Profit / (Loss) from ordinaty activities before

finance costs and Exceptional Items (3+4)
6 Finance costs

(5.82)

(8.14)

(10.81)

0.00
(13.96)

0.15
(20.21)

0.55
(127.77)

0.00

0.00

0.00

7 Profit / (Loss) from ordinary activities after

finance costs but before Exceptional Items (56)
8 Exceptional items

(5.82)

(8.14)

(10.81)

0.00
(13.96)

0.00
(20.21)

0.00
(127.77)

0.00

0.00

28.81

9 Profit / (Loss) from Ordinary Activities before

tax (7+8)

(5.82)

(8.14)

(39.62)

0.00
(13.96)

28.81
(49.02)

0.00
(127.77)

0.00

0.00

0.00

11 Net Profit / (Loss) from Ordinary Activities after tax

(9+10)

(5.82)

(8.14)

(39.62)

0.00
(13.96)

0.00
(49.02)

0.00
(127.77)

12 Extraordinary Item (net of tax expenses)

13 Net Profit / (Loss) for the period (11-12)

0.00
(5.82)

0.00
(8.14)

0.00
(39.62)

0.00
(13.96)

0.00
(49.02)

0.00
(127.77)

800.00

800.00

800.00

0.00

0.00

0.00

800
0.00

800
0.00

Total income from operations (net)

2 2. Expenses

Total
3 Profit / (Loss) from Operations before Other
Income, finance costs and Exceptional Items (12)
4 Other Income

10 Tax expense

14 Paid-up equity share capital (Face value of the

Share shall be indicated) - Face value Rs. 10/15 Reserve excluding Revaluation Reserves as per
balance sheet of previous accounting year

800.00
-

16 i) Earnings per Share (before extraordinary items):

(a) Basic

(0.07)

(0.10)

(0.05)

(0.17)

(0.06)

(1.60)

(b) Diluted

(0.07)

(0.10)

(0.05)

(0.17)

(0.06)

(1.60)

(a) Basic

(0.07)

(0.10)

(0.05)

(0.17)

(0.06)

(1.60)

(b) Diluted

(0.07)

(0.10)

(0.05)

(0.17)

(0.06)

(1.60)

ii) Earning per share (after extraordinary items)

Notes
1.The above Financial Results as recommended by the Audit Comittee were considered and approved by the Board of Directors at their
meeting held on 14th Nov, 2016.
2. The Company is operating in only one segment i.e, Pharmaceuticals and hence segment wise reporting is not made.
3. Previous year/s / period's figures have been regrouped / rearranged / recasted wherever necessary.
For and on behalf of the Board of Directors
Place: Hyderabad
Date : 14.11.2016

DIRECTOR

COMBAT DRUGS LIMITED

(Rs. In Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

30.09.2016
PARTICULARS
UN AUDITED
EQUITY AND LIABILITIES

31.03.2016
AUDITED

1 SHAREHOLDERS'S FUNDS:
a) Share capital
b) Reserves and Surplus
Sub-total - Shareholders Funds

800.00
(601.75)
198.25

800.00
(587.78)
212.22

2 Current Liabilities
a) a) Trade payables
b) b) Other current liabilities
Sub-total - Current Liabilities
TOTAL EQUITY AND LIABILITIES

49.19
28.91
78.10
276.35

39.26
9.24
48.50
260.72

221.95
221.95

221.65
221.65

25.76
19.38
0.12
9.14
54.40
276.35

21.02
7.18
0.28
10.59
39.07
260.72

ASSETS
1 Non-Current Assets
a) Long term loans and advances
Sub-total - Non Current Assets
2 Currest Assets
a) Inventories
b) Trade Receivables
c) Cash and Bank balances
d) Short term loans and advances
Sub-total - Current Assets
TOTAL ASSETS

M. ANANDAM & CO.,

CHARTERED ACCOUNTANTS

INDEPENDENT

AUDITORS'

REVIEW

REPORT ON REVIEW

OF INTERIM

FINANCIAL

RESULTS

To
The Board of Directors of
Combat Drugs Limited

We have reviewed the accompanying Statement of Unaudited Financial Results of Combat Drugs Limited for
the Quarter and six months ended 30th September, 2016. This statement is the responsibility of the
company's Management and has been approved by the Board of Directors. Our responsibility is to issue a
report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of
Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of
Chartered Accountants of India. This standard requires that we plan and perform the review to obtain
moderate assurance as to whether the financial statements are free of material misstatement. A review is
limited primarily to inquiries of company personnel and analytical procedures applied to financial data and
thus provide lessassurance than an audit. We have not performed an audit and accordingly, we do not express
an audit opinion.

Basedon our review conducted as above, nothing has come to our attention that causes us to believe that the
accompanying statement of unaudited financial results prepared in accordance with applicable accounting
standards and other recognized accounting practices and policies has not disclosed the information required
to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, read with Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 and SEBICircular
No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it
contains any material misstatement.
For M. Anandam & Co.,

Place: Hyderabad
Date: 14thNovember, 2016

7' A', SURYA TOWERS, SA ROAR PATEL ROAD, SECUNDERABAD

PHONE :27812377,2781 2034,FAX:2781 2091

Membership NO.018404

- 500 003.